Inhibiting signal transducer and activator of transcription 3: Rationality and rationale design of inhibitors

Expert Opinion on Investigational Drugs

Volumn 20, Issue 9, 2011, Pages 1263-1275

  Mankan, Arun K ^a   Greten, Florian R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Signaling; STAT3; Targeted therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; AZ 960; AZD 1480; CUCURBITACIN; CURCUMIN; CYCLOPENTENONE DERIVATIVE; FLAVOPIRIDOL; INDIRUBIN; INTERLEUKIN 10; INTERLEUKIN 6; N ACYLHOMOSERINE LACTONE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PD 166285; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; RESVERATROL; RGS PROTEIN; SANT 7; STAT3 PROTEIN; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL NUCLEUS; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; CYTOPLASM; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 80051733032     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.601739     Document Type: Review

References (130)

1. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415-21 (Pubitemid 24217131)
2. Darnell JE Jr. STATs and gene regulation. Science 1997;277(9):1630-5 (Pubitemid 27446219)
3. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84(3):331-4 (Pubitemid 26058558)
4. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105 (Pubitemid 38198738)
5. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282(28):20059-63 (Pubitemid 47099977)
6. Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 2000;11(3):199-207 (Pubitemid 30337459)
7. Smithgall TE, Briggs SD, Schreiner S, et al. Control of myeloid differentiation and survival by Stats. Oncogene 2000;19(21):2612-18 (Pubitemid 30339217)
8. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000;19(21):2607-11 (Pubitemid 30339216)
9. Fu XY, Schindler C, Improta T, et al. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992;89(16):7840-3
10. Schindler C, Fu XY, Improta T, et al. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA 1992;89(16):7836-9
11. Levy D, Reich N, Kessler D, et al. Transcriptional regulation of interferon-stimulated genes: a DNA response element and induced proteins that recognize it. Cold Spring Harb Symp Quant Biol 1988;53(Pt 2):799-802 (Pubitemid 20005408)
12. Shuai K, Schindler C, Prezioso VR, et al. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992;258(5089):1808-12 (Pubitemid 23087351)
13. Shuai K, Stark GR, Kerr IM, et al. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993;261(5129):1744-6 (Pubitemid 23332925)
14. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005;5(7):521-31 (Pubitemid 40961330)
15. Yao Z, Cui Y, Watford WT, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 2006;103(4):1000-5 (Pubitemid 43212211)
16. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3(9):651-62 (Pubitemid 34987786)
17. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996;273(5282):1717-19 (Pubitemid 26317788)
18. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 2004;167(2):197-201 (Pubitemid 39435062)
19. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387(6636):917-21 (Pubitemid 27289594)
20. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387(6636):921-4 (Pubitemid 27289595)
21. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387(6636):924-9 (Pubitemid 27289596)
22. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278(5344):1803-5 (Pubitemid 27527648)
23. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998;95(18):10626-31 (Pubitemid 28413118)
24. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000;19(21):2638-44 (Pubitemid 30339220)
25. Akira S, Nishio Y, Inoue M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994;77(1):63-71 •• Identification of STAT3 as an acute phase response protein.
26. Duncan SA, Zhong Z, Wen Z, Darnell JE Jr. STAT signaling is active during early mammalian development. Dev Dyn 1997;208(2):190-8 (Pubitemid 27068874)
27. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997;94(8):3801-4 (Pubitemid 27180453)
28. Takeda K, Kaisho T, Yoshida N, et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998;161(9):4652-60 (Pubitemid 28492039)
29. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10(1):39-49 (Pubitemid 29077382)
30. Sano S, Chan KS, Kira M, et al. Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res 2005;65(13):5720-9 (Pubitemid 40911175)
31. Chapman RS, Lourenco PC, Tonner E, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999;13(19):2604-16 (Pubitemid 29489651)
32. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18(2):254-67 (Pubitemid 351206162)
33. Haftchenary S, Avadisian M, Gunning PT. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anticancer Drugs 2011;22(2):115-27
34. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 2009;1171:59-76
35. Zhang X, Guo A, Yu J, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA 2007;104(10):4060-4 (Pubitemid 47181578)
36. Lufei C, Ma J, Huang G, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003;22(6):1325-35 (Pubitemid 36362696)
37. Herrmann A, Vogt M, Monnigmann M, et al. Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci 2007;120(Pt 18):3249-61 (Pubitemid 350018416)
38. Ma J, Cao X. Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal 2006;18(8):1117-26 (Pubitemid 43674037)
39. Ten Hoeve J, De Jesus Ibarra-Sanchez M, Fu Y, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002;22(16):5662-8 (Pubitemid 34815816)
40. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 2008;19(4):341-50
41. Leslie K, Lang C, Devgan G, et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 2006;66(5):2544-52
42. Tsuruma R, Ohbayashi N, Kamitani S, et al. Physical and functional interactions between STAT3 and KAP1. Oncogene 2008;27(21):3054-9 (Pubitemid 351668002)
43. Suemoto H, Muragaki Y, Nishioka K, et al. Trps1 regulates proliferation and apoptosis of chondrocytes through Stat3 signaling. Dev Biol 2007;312(2):572-81 (Pubitemid 350183980)
44. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13(5):816-25
45. Fujioka S, Niu J, Schmidt C, et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004;24(17):7806-19 (Pubitemid 39121503)
46. Cao X, Tay A, Guy GR, Tan YH. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol 1996;16(4):1595-603 •• Along with [47] the first reports on the role of native and mutated forms of STAT3 in carcinogenesis. (Pubitemid 26095631)
47. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98(3):295-303 (Pubitemid 29380565)
48. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009;457(7226):200-4
49. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10(1):105-15 (Pubitemid 29077388)
50. Karni R, Jove R, Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999;18(33):4654-62 (Pubitemid 29417740)
51. Zushi S, Shinomura Y, Kiyohara T, et al. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998;78(3):326-30 (Pubitemid 28445370)
52. Mahboubi K, Li F, Plescia J, et al. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest 2001;81(3):327-34 (Pubitemid 32245065)
53. Liu H, Ma Y, Cole SM, et al. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 2003;102(1):344-52 (Pubitemid 36759675)
54. Bhattacharya S, Schindler C. Regulation of Stat3 nuclear export. J Clin Invest 2003;111(4):553-9 (Pubitemid 36228012)
55. Xie TX, Wei D, Liu M, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004;23(20):3550-60 (Pubitemid 38658421)
56. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008;28(2):185-200 (Pubitemid 351281185)
57. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49 (Pubitemid 351656458)
58. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21(13):2000-8 (Pubitemid 34270888)
59. Cheng GZ, Zhang WZ, Sun M, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008;283(21):14665-73
60. Real PJ, Sierra A, De Juan A, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21(50):7611-18 (Pubitemid 35398808)
61. Choi CH, Song SY, Kang H, et al. Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. J Obstet Gynaecol Res 2010;36(2):304-10
62. Wegrzyn J, Potla R, Chwae YJ, et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009;323(5915):793-7 •• Along with [63] these studies reported on the unsual localization of STAT3 in mitochondria and its functional significance.
63. Gough DJ, Corlett A, Schlessinger K, et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009;324(5935):1713-16
64. Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002;169(11):6610-16 (Pubitemid 36903515)
65. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003;3(3):317-22 (Pubitemid 36686774)
66. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6(5):583-8 (Pubitemid 30305911)
67. Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003;278(19):16777-81 (Pubitemid 36799545)
68. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999;36(13-14):949-55 (Pubitemid 30100847)
69. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118(3):285-96 •• The key study identified the link between inflammation and carcinogenesis. (Pubitemid 39061110)
70. Bollrath J, Phesse TJ, Von Burstin VA, et al. Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15(2):91-102 •• The first report linking STAT3 and inflammation-induced carcninogenesis.
71. Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008;118(5):1727-38 (Pubitemid 351632376)
72. Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009;10(12):1314-19
73. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15(2):103-13
74. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-99 • This review exhaustively covers the link between inflammation and cancer.
75. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10(1):48-54 (Pubitemid 38524698)
76. Albesiano E, Davis M, See AP, et al. Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. Cancer Res 2010;70(16):6467-76
77. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11(12):1314-21 (Pubitemid 41752912)
78. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441(7090):235-8
79. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008;205(7):1551-7 (Pubitemid 351962018)
80. Kesselring R, Thiel A, Pries R, et al. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 2010;103(8):1245-54
81. Bronte V. Th17 and cancer: friends or foes? Blood 2008;112(2):214
82. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62(22):6659-66 (Pubitemid 35364135)
83. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59(20):5059-63 (Pubitemid 29503958)
84. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97(8):4227-32 (Pubitemid 30226115)
85. Anderson KC, Kyle RA, Dalton WS, et al. Multiple myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program 2000;2000:147-65
86. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448(7157):1058-62 (Pubitemid 47345590)
87. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357(16):1608-19 (Pubitemid 47598403)
88. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19(56):6613-26 (Pubitemid 32197700)
89. Aubert-Jurgens A. STAT3 inhibitors for cancer treatment. PhD Dissertation; 2005
90. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008;3(8):1159-68
91. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276(48):45443-55
92. Ren Z, Cabell LA, Schaefer TS, McMurray JS. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett 2003;13(4):633-6 (Pubitemid 36298456)
93. Nagel-Wolfrum K, Buerger C, Wittig I, et al. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2004;2(3):170-82 (Pubitemid 39030307)
94. Buerger C, Nagel-Wolfrum K, Kunz C, et al. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem 2003;278(39):37610-21 (Pubitemid 37175284)
95. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3(12):1533-42 (Pubitemid 40136708)
96. Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005;280(38):32979-88 (Pubitemid 41368347)
97. Siddiquee KA, Gunning PT, Glenn M, et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2007;2(12):787-98 (Pubitemid 351166054)
98. Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13(11):1235-42 (Pubitemid 44750735)
99. Jing N, Li Y, Xiong W, et al. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004;64(18):6603-9 (Pubitemid 39297920)
100. Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 2007;31(1):129-36
101. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;100(7):4138-43 (Pubitemid 36418170)
102. Gu J, Li G, Sun T, et al. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 2008;89(1):9-17
103. Vuorelaa P, Leinonenb M, Saikkuc P, et al. Natural products in the process of finding new drug candidates. Curr Med Chem 2004;11(11):1375-89
104. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007;7(1):91-107 (Pubitemid 46345511)
105. Vogel E, Pelletier S. J Pharm. 2(1815):50
106. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 2009;11(3):495-510
107. Huang MT, Wang ZY, Georgiadis CA, et al. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7, 12-dimethylbenz[a]anthracene. Carcinogenesis 1992;13(11):2183-6
108. Conney AH, Lysz T, Ferraro T, et al. Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul 1991;31:385-96
109. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171(7):3863-71 (Pubitemid 37254592)
110. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005;24(47):7022-30 (Pubitemid 41573631)
111. Wung BS, Hsu MC, Wu CC, Hsieh CW. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci 2005;78(4):389-97 (Pubitemid 41597548)
112. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000;164(12):6509-19 (Pubitemid 30408836)
113. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999;163(6):3474-83 (Pubitemid 29431852)
114. Lee YK, Isham CR, Kaufman SH, Bible KC. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther 2006;5(1):138-48
115. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102(13):4700-5 (Pubitemid 40471517)
116. Weidler M, Rether J, Anke T, Erkel G. Inhibition of interleukin-6 signaling and Stat3 activation by a new class of bioactive cyclopentenone derivatives. Biochem Biophys Res Commun 2000;276(2):447-53
117. Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem 2006;281(33):23425-35 (Pubitemid 44274117)
118. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20(20):2499-513 (Pubitemid 32531347)
119. Laird AD, Li G, Moss KG, et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and-independent growth of human tumor cells. Mol Cancer Ther 2003;2(5):461-9
120. Li B, Chang CM, Yuan M, et al. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003;63(21):7443-50 (Pubitemid 37413487)
121. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112(6):2190-8
122. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008;59:213-22 (Pubitemid 351287934)
123. Greten FR, Karin M. Peering into the aftermath: JAKi rips STAT3 in cancer. Nat Med 2010;16(10):1085-7
124. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379(6566):645-8 (Pubitemid 26053453)
125. Scuto A, Krejci P, Popplewell L, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011;25:538-50 •• Along with [126] these studies identified JAK2 inhibitors as promising STAT3 inhibiting candidates.
126. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16(6):487-97
127. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007;102(2):129-35 (Pubitemid 46452175)
128. Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis 2010;25(2):135-40
129. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580-4
130. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66(11):5542-8 (Pubitemid 43927102)